Excessive Daytime Sleepiness — Causes, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Excessive daytime sleepiness (EDS) is the inability to maintain wakefulness and alertness during the major waking periods of the day, resulting in unintended lapses into drowsiness or sleep. It is one of the most common presenting complaints in sleep medicine — affecting 10-20% of the general adult population — and is associated with significantly impaired quality of life, reduced occupational performance, increased accident risk (road traffic accidents — 2-7x higher in people with EDS), and impaired cognitive function. EDS must be distinguished from fatigue (a subjective lack of energy without the tendency to actually fall asleep). The Epworth Sleepiness Scale (ESS) quantifies subjective daytime sleepiness — a score above 10 is clinically significant; above 16 is severe. EDS has numerous causes, ranging from the most common (obstructive sleep apnoea, insufficient sleep syndrome) to less common but important conditions (narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome) — careful clinical assessment and sleep laboratory testing are required to identify the specific diagnosis and guide appropriate treatment.

Insufficient sleep syndrome: the most common cause — chronic sleep deprivation from lifestyle (shift work, poor sleep habits, long working hours); resolves with adequate sleep extension. Obstructive sleep apnoea (OSA): repetitive upper airway collapse during sleep causing arousals and non-restorative sleep; the most common medical cause of EDS — affects 936 million adults globally; associated with obesity, male sex, age, and craniofacial anatomy. Narcolepsy Type 1 (with cataplexy): caused by autoimmune destruction of hypothalamic hypocretin (orexin)-producing neurons — CSF hypocretin below 110 pg/mL is diagnostic; presents with EDS, cataplexy (sudden loss of muscle tone triggered by emotion — laughter, excitement — pathognomonic), sleep paralysis, hypnagogic hallucinations, and disrupted nocturnal sleep. Narcolepsy Type 2 (without cataplexy): similar EDS without cataplexy; CSF hypocretin normal. Idiopathic hypersomnia: EDS without the REM-related features of narcolepsy; long, unrefreshing sleep episodes; severe sleep inertia ('sleep drunkenness'). Central disorders: brain tumours, head injury, encephalitis. Circadian rhythm disorders: shift work disorder, delayed sleep-wake phase disorder. Medications: opioids, benzodiazepines, antihistamines, antipsychotics, anticonvulsants. Medical comorbidities: hypothyroidism, diabetes, renal failure, anaemia, cardiac failure, depression. Kleine-Levin syndrome: rare recurrent hypersomnia in adolescents with episodic hypersomnia lasting days-weeks.

Core symptom: overwhelming urge to sleep during the day — unintentional sleep episodes during sedentary activities (watching television, reading), active activities (eating, talking, driving), and in severe cases during ongoing activity. Epworth Sleepiness Scale (ESS): validated 8-item questionnaire rating likelihood of dozing in 8 situations (0-24 points) — above 10 indicates significant EDS; used for screening and monitoring treatment response. Narcolepsy-specific symptoms: cataplexy (sudden bilateral muscle weakness — ranges from facial drooping or slurred speech to complete falls, triggered by strong emotions; pathognomonic of narcolepsy type 1); hypnagogic or hypnopompic hallucinations (vivid, often frightening, dream-like hallucinations on falling asleep or waking — due to intrusion of REM sleep into wakefulness); sleep paralysis (transient inability to move during sleep-wake transition). OSA-specific: loud snoring, witnessed apnoeas, nocturia, morning headache, and a history of obesity or craniofacial abnormality. Impact assessment: difficulty maintaining wakefulness at work, poor concentration, memory difficulties, irritability, and impaired driving — patients should be specifically asked about driving history and instructed not to drive if EDS is significant, pending assessment and treatment.

Clinical assessment: detailed sleep history (bedtime, wake time, total sleep time, sleep quality, napping), sleep diary (2-week diary before sleep studies), Epworth Sleepiness Scale, Morningness-Eveningness Questionnaire, and review of all medications. Actigraphy (wrist-worn activity monitor): objective measurement of rest-activity cycles over 7-14 days — identifies circadian rhythm abnormalities and estimates sleep duration. Polysomnography (PSG — overnight sleep study): measures EEG, EOG, EMG, ECG, airflow, respiratory effort, oximetry, and limb movements in a sleep laboratory. Essential for diagnosis of OSA (apnoea-hypopnoea index — AHI; above 15 events/hour is moderate-severe OSA), periodic limb movements, and REM sleep behaviour disorder. Also used in narcolepsy assessment (characteristic sleep-onset REM periods — SOREMPs). Multiple Sleep Latency Test (MSLT): performed the day after PSG — five 20-minute nap opportunities at 2-hourly intervals; mean sleep onset latency below 8 minutes indicates pathological sleepiness; 2 or more SOREMPs indicates narcolepsy. Lumbar puncture for CSF hypocretin-1: essential for confirming narcolepsy type 1 (CSF hypocretin below 110 pg/mL) and differentiating from type 2. HLA-DQB1*0602 typing: positive in >90% of narcolepsy type 1 (highly sensitive but not specific). Thyroid function and blood tests to exclude metabolic causes.

OSA treatment: continuous positive airway pressure (CPAP) — the gold standard for moderate-severe OSA; maintains upper airway patency during sleep, abolishes apnoeas, and dramatically improves daytime sleepiness, blood pressure, and cardiovascular risk. Mandibular advancement device (MAD): effective for mild-moderate OSA and CPAP-intolerant patients. Weight loss: clinically meaningful OSA improvement with 10%+ weight loss in obese patients. Positional therapy: for position-dependent OSA (supine-predominant). Surgical options: UPPP, maxillomandibular advancement, and implantable hypoglossal nerve stimulator (Inspire) for CPAP-intolerant patients with appropriate anatomy. Narcolepsy (EDS): modafinil (100-400 mg/day — first-line wakefulness agent), pitolisant (histamine H3 receptor antagonist/inverse agonist — approved UK and EU; also improves cataplexy), solriamfetol (dopamine/noradrenaline reuptake inhibitor), and dextroamphetamine or methylphenidate (second-line). Cataplexy: sodium oxybate (sodium gamma-hydroxybutyrate — oxybate) is the most effective agent for cataplexy and also improves nocturnal sleep and EDS; venlafaxine and clomipramine are alternatives. Low-sodium oxybate (Lumryz) — once-nightly formulation. Idiopathic hypersomnia: modafinil; low-sodium oxybate approved by FDA 2021 for idiopathic hypersomnia. Insufficient sleep syndrome: sleep extension, sleep hygiene education, CBT-I (cognitive behavioural therapy for insomnia). Shift work: strategic napping, melatonin, and modified schedules.

The most dangerous complication of untreated EDS is road traffic accidents — people with EDS have a 2–7x higher accident risk; narcolepsy without adequate treatment represents a serious driver safety hazard and must be notified to the DVLA. For narcolepsy patients, the average diagnostic delay is 10 years — during which severe disability, depression, educational failure, and occupational dysfunction accumulate unaddressed. Cardiovascular complications include elevated blood pressure and metabolic syndrome from the underlying untreated OSA in those where this is the cause. Cognitive impairment (memory, executive function, sustained attention) from chronic sleep deprivation and sleep fragmentation significantly reduces academic and occupational performance. Depression and anxiety are comorbid in up to 50% of patients with narcolepsy or idiopathic hypersomnia, contributing substantially to quality-of-life burden. Social stigma — sleep attacks misinterpreted as disinterest, laziness, or drug use — causes significant social isolation. Occupational accidents from machinery and falls are elevated in patients with significant uncontrolled EDS.

Insufficient sleep prevention: prioritise sleep duration (adults 7-9 hours, teenagers 8-10 hours); maintain consistent sleep and wake times (including weekends); limit caffeine to before 14:00; avoid alcohol within 3 hours of bedtime (disrupts sleep architecture); create a cool, dark, quiet sleep environment; limit screen use in the hour before sleep (blue light suppresses melatonin). OSA risk reduction: weight management (BMI below 25 reduces OSA risk substantially); avoid alcohol and muscle relaxants before sleep (worsen upper airway tone); avoid supine sleeping position if OSA is position-dependent; treat nasal congestion. Narcolepsy prevention: not preventable, as it involves autoimmune destruction of hypocretin neurons — however, early diagnosis and treatment prevents years of unrecognised disability. Driving safety: patients with significant EDS should not drive until their sleep disorder is adequately treated and symptoms are controlled — a legal and safety responsibility. DVLA notification is required for narcolepsy, and for OSA with an AHI above 15 combined with EDS symptoms, in the UK.

See your GP promptly if: daytime sleepiness is affecting your ability to work, drive, or carry out daily activities; your partner witnesses you stopping breathing during sleep (apnoea episodes); you have experienced a drowsy-driving near-miss or road traffic accident; or you have had sudden episodes of muscle weakness triggered by emotion (possible cataplexy — seek specialist review urgently as narcolepsy is often not diagnosed for many years). Seek emergency care if: you have experienced a road traffic accident due to falling asleep at the wheel, sudden collapse with muscle weakness (cataplexy may mimic seizure or cardiac syncope), or severe disruption of breathing during sleep. Patients with untreated significant EDS have a 2-7x increased risk of motor vehicle accidents and should not drive pending assessment — this is both a safety and a legal issue. Inform the DVLA (UK) or equivalent licensing authority of a sleep disorder affecting driving ability.